ArticleCommunications biology2026
Identification of intracellular target of antimicrobial peptide EWAMP-R in bacteria.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Next-Generation Antimicrobial Peptides for Biofilm-Associated Infections: Engineering, Biomaterial Delivery and AI-Assisted Discovery.Antibiotics (Basel, Switzerland) · 2026Review
- Membrane-Targeted Consequences of Acetaminophen Toxicity and Off-Target Effects of Antimicrobial Peptides on Host Cell Membranes.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Antimicrobial peptides (AMPs) exhibit diverse antibacterial mechanisms. To elucidate the intracellular targets of the novel AMP, EWAMP-R, we generate EWAMP-R-resistant strains of Escherichia coli and Staphylococcus aureus. In E. coli, a nonsynonymous mutation in the clpX gene (1108 C > T) is identified, resulting in an amino acid change in ClpX (R370C). This mutation confers enhanced tolerance to EWAMP-R and induces a "hyperflagellate phenotype" in EWAMP-R-resistant E. coli, as verified by CRISPR/Cas9-generated clpX (1108 C > T) mutants. Further studies reveal that EWAMP-R can bind to the Walker A motif and inhibit the conformational changes of ClpX, suppressing its ATPase activity and the degradation of its substrates, such as LexA 1-84. The accumulation of LexA 1-84 downregulates the SOS response, inducing apoptosis-like death in E. coli. In contrast, EWAMP-R-resistant S. aureus exhibits only a metabolic slowdown. These findings establish ClpX as a novel target for AMPs and highlight EWAMP-R as a promising antibacterial agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.